Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

STRIVERDI RESPIMAT INHAL SPRAY

olodaterol respimat inhalation spray
$65.9853per GM

Strength

2.5 ug/1

Manufacturer

Boehringer Ingelheim Pharmaceuticals Inc.

NDC

00597019261

Classification

Brand

Dosage Form

SPRAY, METERED

Route

RESPIRATORY (INHALATION)

Last Updated

1/1/2026

Active Ingredients

OLODATEROL HYDROCHLORIDE

Approval Type

New Drug (NDA)

FDA Application

NDA203108

On Market Since

8/1/2014

Pharmacological Classes

Adrenergic beta2-Agonists
beta2-Adrenergic Agonist

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+3.1%

1Y

+2.8%

3Y

+9.7%

5Y

+18.0%

All

+76.0%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

ADVAIR 100-50 DISKUS
Brand
00173069500•GlaxoSmithKline LLC
$2.4867
per EA
VENTOLIN HFA 90 MCG INHALER
Brand
00173068224•GlaxoSmithKline LLC
$2.7222
per GM
VENTOLIN HFA 90 MCG INHALER
Brand
00173068220•GlaxoSmithKline LLC
$3.0358
per GM
ADVAIR 250-50 DISKUS
Brand
00173069604•GlaxoSmithKline LLC
$3.1083
per EA
ADVAIR 250-50 DISKUS
Brand
00173069600•GlaxoSmithKline LLC
$3.1228
per EA
ADVAIR 500-50 DISKUS
Brand
00173069700•GlaxoSmithKline LLC
$4.2290
per EA
XOPENEX HFA 45 MCG INHALER
Brand
27437005601•Lupin Pharmaceuticals Inc.
$5.0542
per GM
BREO ELLIPTA 200-25 MCG INHALR
Brand
00173088214•GlaxoSmithKline LLC
$5.3628
per EA
BREO ELLIPTA 100-25 MCG INHALR
Brand
00173085914•GlaxoSmithKline LLC
$5.3663
per EA
BREO ELLIPTA 50-25 MCG INHALER
Brand
00173091610•GlaxoSmithKline LLC
$6.4848
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy